CNBXOTCPharmaceutical PreparationsFiscal year ends August 31

CNBX Pharmaceuticals Inc.

Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jun 24, 2026

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2011 to 2025

–

–

–

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	79.1%	-90.5%	12.6%
Return on assets	-1172.0%	-85.8%	-1260.4%
Current ratio	0.04	2.04	0.01
Interest coverage	-39.1×	–	-6.8×
Diluted shares	103M	135M	91M

Return on equity split into margin, efficiency and leverage

Net margin-534.5%

Asset turnover0.49×

Equity multiplier-0.12×

Return on equity, FY202430.9%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2024	-534.5%	0.49×	-0.12×	30.9%
FY2023	-904.6%	0.63×	-3.40×	1927.5%
FY2022	-12428.2%	0.02×	1.13×	-216.6%
FY2020	-104337.9%	0.00×	1.05×	-90.5%
FY2019	11510.4%	0.00×	1.06×	13.0%
FY2018	-39335.7%	0.00×	-23.28×	2576.9%
FY2017	-34022.5%	0.00×	-1.07×	113.6%
FY2016	-273.0%	4.29×	-0.07×	79.1%

Parsed from the XBRL in CNBX Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-120 reverse split on May 12, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CNBX.

Advertisement
300 × 250